The relationship between KRAS and MYC in tumorigenesis is very complex but BET inhibition in mouse models of KRAS-driven PDAC and NSCLC reduced both tumor size and tumor grade [44, 45]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.